The KCTD1 Knockout HAP1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population of HAP1 cells providing a loss-of-function model of the KCTD1 gene. This heterogeneous pool carries targeted KCTD1 disruptions, enabling analysis of gene function without clonal artifacts. The polyclonal format preserves genetic diversity while ensuring functional gene disruption, ideal for studying KCTD1-dependent processes.
HAP1 is a near-haploid chronic myeloid leukemia cell line derived from a male patient, with adherent, fibroblast-like morphology. Its near-haploid karyotype facilitates efficient CRISPR/Cas9-mediated gene disruption, making it a standard host for functional genomics. While retaining myeloid progenitor characteristics, HAP1 enables investigation of signaling pathways relevant to both hematological and solid tumor biology.
KCTD1 acts as a substrate adaptor for the CUL3-RBX1 E3 ubiquitin ligase complex, directing ubiquitination and proteasomal degradation of ??-catenin, GLI1, and HDAC1. This activity suppresses Wnt/??-catenin and Hedgehog signaling, regulating transcriptional programs controlling proliferation, differentiation, and apoptosis. KCTD1 also interacts with AP-2?? and SUMOylated proteins, contributing to transcriptional repression. Consequently, KCTD1 functions as a tumor suppressor and critical regulator of craniofacial development, with its disruption linked to cancers and developmental syndromes.
In the HAP1 background, KCTD1 loss de-represses Wnt and Hedgehog signaling, mimicking oncogenic activation seen in medulloblastoma, colorectal, and breast cancers. The near-haploid, polyclonal system provides a simplified platform to dissect KCTD1??s tumor-suppressive functions and study ubiquitin-proteasome-dependent signaling control. This model recapitulates key molecular events of KCTD1 inactivation without clonal selection bias, enabling robust investigation of genotype-phenotype relationships and signaling crosstalk in a leukemic cell context.
This knockout model supports diverse applications: CRISPR validation and drug target identification using ??-catenin/TCF and GLI-luciferase reporter assays; biochemical interrogation via ubiquitination assays, co-immunoprecipitation, and Western blotting; and transcriptional profiling using RNA-seq and RT-qPCR. Phenotypic assays for proliferation, apoptosis, and immunofluorescence further characterize functional consequences of KCTD1 loss. For technical inquiries, contact Ascent Research.
